FDA grants priority review to Gilead's HIV co-formulation

July 2004
PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p13
Market Research Report
Reports on the approval of the U.S. Food and Drug Administration to Gilead Sciences Inc.'s New Drug Application for the fixed dose co-formulation of the anti-HIV medications Viread and Emtriva. Terms under the priority review; Designation granted to drugs; Administration of the proposed co-formulated tablet.


Related Articles

  • U.S. FDA Grants Priority Review for Truvada(r) for Reducing the Risk of Acquiring HIV Infection.  // Biomedical Market Newsletter;2/14/2012, Vol. 21, p1 

    The article offers information related to an announcement made by Gilead Sciences Inc. regarding acceptance and approval of its supplemental New Drug Application by the U.S. Food and Drug Administration. Truvada, a registered trademark of Gilead Sciences Inc. is the first agent which is...

  • Doctors to FDA: "HIV Prevention Pill" Not Ready for Approval.  // Biomedical Market Newsletter;7/5/2011, p299 

    The article reports on the letter sent by 55 physicians in the U.S. to the U.S. Food and Drug Administration (FDA) on not to approve the use of HIV/AIDS treatment drug Truvada from Gilead Sciences Inc. as HIV prevention pill. It says that the letter headed by the AIDS Healthcare Foundation (AHF)...

  • FDA approves Amgen's drug for chronic kidney disease.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration to Amgen Inc.'s Sensipar drug targeting chronic kidney disease. Classification of Sensipar; Safety and efficacy of the drug; Response of patients taking Sensipar.

  • ImClone wins FDA approval for Erbitux.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration (FDA) to ImClone Systems Inc.'s Erbitux designated to treat advanced colorectal cancer. Impact of the approval of the FDA on the operation of the company; Evidence showing the safety and efficacy of Erbitux; Response of patients...

  • Other News To Note.  // BioWorld Today;12/19/2011, Vol. 22 Issue 243, p5 

    This section offers news briefs on the biopharmaceutical market. A supplemental new drug application was submitted by Gilead Sciences Inc. to the U.S. Food and Drug Administration for Truvada. An unsolicited acquisition bid from Valeant Pharmaceuticals International Inc. was rejected by the...

  • US Food and Drug Administration Approves Gilead's Once-Daily HIV Pill.  // Clinical Infectious Diseases;11/1/2011, Vol. 53 Issue 9, preceding p853 

    The article provides information on the approval of once daily experimental Human Immunodeficiency Virus drug from Gilead Sciences Inc. by the U.S. Food and Drug Administration.

  • 'Btripla' Gets Surprise RTF; Gilead Asked for More Data.  // BioWorld Today;1/26/2011, Vol. 22 Issue 17, p2 

    This article reports on the refuse-to-file letter received by Gilead Sciences Inc. from the U.S. Food and Drug Administration for its new drug application seeking approval of human immunodeficiency virus single-tablet regimen Truvada plus TMC278 from Tibotec Pharmaceuticals Inc.

  • FDA decision on the approval of Truvada for PrEP delayed three months.  // HIV Australia;Jun2012, Vol. 10 Issue 1, p4 

    The article reports that the Food and Drug Administration (FDA) has extended its review until September 14, 2012 on Gilead Sciences Inc.'s approval application of the drug Truvada for pre-exposure prophylaxis (PrEP).

  • Viread for Treating Children.  // Monthly Prescribing Reference;Feb2012, Vol. 28 Issue 2, pA14 

    The article reports the U.S. Food and Drug Administration's approval for the use of the drug Viread from Gilead Sciences Inc. along with other antiretroviral agents for treating children.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics